Shares of Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) have received an average rating of “Hold” from the twenty-one analysts that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $15.24.

Several equities analysts have issued reports on MDRX shares. BidaskClub upgraded shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Piper Jaffray Companies restated a “hold” rating and issued a $14.00 price target on shares of Allscripts Healthcare Solutions in a research report on Friday, July 21st. Maxim Group restated a “buy” rating and issued a $16.00 price target on shares of Allscripts Healthcare Solutions in a research report on Friday, August 4th. Morgan Stanley upped their price target on shares of Allscripts Healthcare Solutions from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Monday, August 7th. Finally, Citigroup Inc. upped their price target on shares of Allscripts Healthcare Solutions from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, August 7th.

COPYRIGHT VIOLATION NOTICE: This story was first published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/19/allscripts-healthcare-solutions-inc-mdrx-given-consensus-recommendation-of-hold-by-brokerages.html.

Shares of Allscripts Healthcare Solutions (NASDAQ:MDRX) traded up 0.22% during trading on Thursday, reaching $13.95. 1,113,871 shares of the company’s stock were exchanged. Allscripts Healthcare Solutions has a 52-week low of $9.80 and a 52-week high of $14.45. The stock’s 50 day moving average price is $13.78 and its 200-day moving average price is $12.69. The stock’s market cap is $2.52 billion.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last announced its quarterly earnings results on Thursday, August 3rd. The software maker reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.15 by ($0.04). Allscripts Healthcare Solutions had a negative net margin of 11.54% and a positive return on equity of 5.97%. The business had revenue of $426.10 million during the quarter, compared to analyst estimates of $424.94 million. During the same quarter last year, the company posted $0.14 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. On average, equities research analysts forecast that Allscripts Healthcare Solutions will post $0.61 EPS for the current year.

In related news, EVP Brian Farley sold 5,000 shares of the stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $13.52, for a total transaction of $67,600.00. Following the transaction, the executive vice president now directly owns 196,607 shares of the company’s stock, valued at $2,658,126.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Paul Black sold 15,000 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $13.52, for a total transaction of $202,800.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,000 shares of company stock worth $473,800. 0.75% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. World Asset Management Inc boosted its stake in Allscripts Healthcare Solutions by 0.7% during the second quarter. World Asset Management Inc now owns 11,419 shares of the software maker’s stock worth $146,000 after acquiring an additional 81 shares in the last quarter. Advantus Capital Management Inc boosted its stake in Allscripts Healthcare Solutions by 0.5% during the first quarter. Advantus Capital Management Inc now owns 23,112 shares of the software maker’s stock worth $293,000 after acquiring an additional 109 shares in the last quarter. Atlantic Trust Group LLC boosted its stake in Allscripts Healthcare Solutions by 0.3% during the second quarter. Atlantic Trust Group LLC now owns 32,900 shares of the software maker’s stock worth $420,000 after acquiring an additional 110 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Allscripts Healthcare Solutions by 0.4% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,484 shares of the software maker’s stock worth $338,000 after acquiring an additional 115 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in Allscripts Healthcare Solutions by 6.9% during the second quarter. Bank of Montreal Can now owns 10,603 shares of the software maker’s stock worth $135,000 after acquiring an additional 689 shares in the last quarter.

Allscripts Healthcare Solutions Company Profile

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.